Tags

Type your tag names separated by a space and hit enter

Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis.
Scand J Rheumatol 2007 Sep-Oct; 36(5):345-50SJ

Abstract

OBJECTIVE

The aim of the study was to analyse serum concentrations of soluble cell adhesion molecules (CAMs) in patients with early rheumatoid arthritis (RA) before and after 6 months of treatment with methotrexate (MTX).

METHODS

We studied 32 RA patients, untreated with disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids, with disease duration less than 3 years. Twenty osteoarthritis (OA) patients constituted the control group. The analysis of serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1), and E-selectin (sE-selectin) was based on a quantitative sandwich enzyme-linked immunosorbent assay (ELISA).

RESULTS

In comparison with OA patients, higher serum concentrations of sICAM-1 (p<0.01), sVCAM-1 (p<0.01), and sE-selectin (p<0.05) were observed in untreated patients with early RA. Six months of treatment with MTX down-regulated serum concentrations of sICAM-1, sVCAM-1, and sE-selectin (in all cases p<0.001) in the RA patients studied. MTX treatment was also followed by a decrease in the clinical markers of RA activity, such as the number of painful and swollen joints, erythrocyte sedimentation rate (ESR), disease activity score (DAS), and C-reactive protein (CRP) levels.

CONCLUSIONS

Patients with early RA are characterized by high serum concentrations of sICAM-1, sVCAM-1, and sE-selectin. Therapy with MTX resulted in clinical improvement and diminished serum levels of soluble CAMs in the RA patients studied, confirming the effectiveness of MTX in early stages of the disease.

Authors+Show Affiliations

Department of Rheumatology and Internal Diseases, Medical University of Bialystok, Bialystok, Poland. klimp@amb.edu.plNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17963163

Citation

Klimiuk, P A., et al. "Soluble Cell Adhesion Molecules (sICAM-1, sVCAM-1, and sE-selectin) in Patients With Early Rheumatoid Arthritis." Scandinavian Journal of Rheumatology, vol. 36, no. 5, 2007, pp. 345-50.
Klimiuk PA, Fiedorczyk M, Sierakowski S, et al. Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scand J Rheumatol. 2007;36(5):345-50.
Klimiuk, P. A., Fiedorczyk, M., Sierakowski, S., & Chwiecko, J. (2007). Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. Scandinavian Journal of Rheumatology, 36(5), pp. 345-50.
Klimiuk PA, et al. Soluble Cell Adhesion Molecules (sICAM-1, sVCAM-1, and sE-selectin) in Patients With Early Rheumatoid Arthritis. Scand J Rheumatol. 2007;36(5):345-50. PubMed PMID: 17963163.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) in patients with early rheumatoid arthritis. AU - Klimiuk,P A, AU - Fiedorczyk,M, AU - Sierakowski,S, AU - Chwiecko,J, PY - 2007/10/27/pubmed PY - 2007/12/22/medline PY - 2007/10/27/entrez SP - 345 EP - 50 JF - Scandinavian journal of rheumatology JO - Scand. J. Rheumatol. VL - 36 IS - 5 N2 - OBJECTIVE: The aim of the study was to analyse serum concentrations of soluble cell adhesion molecules (CAMs) in patients with early rheumatoid arthritis (RA) before and after 6 months of treatment with methotrexate (MTX). METHODS: We studied 32 RA patients, untreated with disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids, with disease duration less than 3 years. Twenty osteoarthritis (OA) patients constituted the control group. The analysis of serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVCAM-1), and E-selectin (sE-selectin) was based on a quantitative sandwich enzyme-linked immunosorbent assay (ELISA). RESULTS: In comparison with OA patients, higher serum concentrations of sICAM-1 (p<0.01), sVCAM-1 (p<0.01), and sE-selectin (p<0.05) were observed in untreated patients with early RA. Six months of treatment with MTX down-regulated serum concentrations of sICAM-1, sVCAM-1, and sE-selectin (in all cases p<0.001) in the RA patients studied. MTX treatment was also followed by a decrease in the clinical markers of RA activity, such as the number of painful and swollen joints, erythrocyte sedimentation rate (ESR), disease activity score (DAS), and C-reactive protein (CRP) levels. CONCLUSIONS: Patients with early RA are characterized by high serum concentrations of sICAM-1, sVCAM-1, and sE-selectin. Therapy with MTX resulted in clinical improvement and diminished serum levels of soluble CAMs in the RA patients studied, confirming the effectiveness of MTX in early stages of the disease. SN - 0300-9742 UR - https://www.unboundmedicine.com/medline/citation/17963163/Soluble_cell_adhesion_molecules__sICAM_1_sVCAM_1_and_sE_selectin__in_patients_with_early_rheumatoid_arthritis_ L2 - http://www.tandfonline.com/doi/full/10.1080/03009740701406460 DB - PRIME DP - Unbound Medicine ER -